Soluble plasma HLA peptidome as a potential source for cancer biomarkers

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 44, 2010, Pages 18769-18776

  Bassani Sternberg, Michal ^a   Barnea, Eilon ^a   Beer, Ilan ^b   Avivi, Irit ^a   Katz, Tami ^a   Admon, Arie ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b IBM HAIFA RESEARCH LAB   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ATP DEPENDENT RNA HELICASE A PROTEIN; BUTYRATE RESPONSE FACTOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR SUBSTRATE 15 PROTEIN; FORKHEAD BOX PROTEIN P1; HLA ANTIGEN; MYELOID DIFFERENTIATION FACTOR 88; RAS RELATED PROTEIN RAB 32; RIBOSOMAL PROTEIN S6 KINASE ALPHA 1; TESTIS EXPRESSED SEQUENCE 10 PROTEIN; TESTISIN; TRANSCRIPTION FACTOR JUNB; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; AMINO ACID SEQUENCE; ANTIBODY AFFINITY; CANCER CELL CULTURE; CANCER DIAGNOSIS; CANCER PATIENT; CELL MEMBRANE; CONFERENCE PAPER; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; HAPLOTYPE; HUMAN; HUMAN CELL; LEUKEMIA CELL; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MULTIPLE MYELOMA; MYELOMA CELL; PEPTIDOMICS; PLASMA CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN MOTIF; PROTEIN PURIFICATION; PROTEIN SYNTHESIS; VALIDATION PROCESS;

EID: 78650443580     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1008501107     Document Type: Article

References (44)

1. Liotta LA, Petricoin EF (2006) Serum peptidome for cancer detection: Spinning biologic trash into diagnostic gold. J Clin Invest 116:26-30.
2. Lopez MF, et al. (2005) High-resolution serum proteomic profiling of Alzheimer disease samples reveals disease-specific, carrier-protein-bound mass signatures. Clin Chem 51:1946-1954.
3. Lowenthal MS, et al. (2005) Analysis of albumin-associated peptides and proteins from ovarian cancer patients. Clin Chem 51:1933-1945.
4. Villanueva J, et al. (2006) Serum peptidome patterns that distinguish metastatic thyroid carcinoma from cancer-free controls are unbiased by gender and age. Mol Cell Proteomics 5:1840-1852.
5. Villanueva J, et al. (2006) Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 116:271-284.
6. Rammensee HG (2006) Peptides made to order. Immunity 25:693-695.
7. Purcell AW, McCluskey J, Rossjohn J (2007) More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov 6:404-414.
8. Admon A, Barnea E, Ziv T (2003) Tumor antigens and proteomics from the point of view of the major histocompatibility complex peptides. Mol Cell Proteomics 2:388-398.
9. Albitar M, et al. (2007) Levels of soluble HLA-I and beta2M in patients with acute myeloid leukemia and advanced myelodysplastic syndrome: Association with clinical behavior and outcome of induction therapy. Leukemia 21:480-488.
10. Albitar M, et al. (2007) Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease. Leuk Res 31:139-145.
11. Leleu X, et al. (2005) Total soluble HLA class I and soluble HLA-G in multiple myeloma and monoclonal gammopathy of undetermined significance. Clin Cancer Res 11:7297-7303.
12. Nocito M, Montalban C, Gonzalez-Porque P, Villar LM (1997) Increased soluble serum HLA class I antigens in patients with lymphoma. Hum Immunol 58:106-111.
13. Shimura T, et al. (2001) Clinical significance of soluble form of HLA class I molecule in Japanese patients with pancreatic cancer. Hum Immunol 62:615-619.
14. Tsuchiya N, Shiota M, Yamaguchi A, Ito K (1996) Elevated serum level of soluble HLA class I antigens in patients with systemic lupus erythematosus. Arthritis Rheum 39:792-796.
15. Moore C, et al. (1997) Elevated levels of soluble HLA class I (sHLA-I) in children with severe atopic dermatitis. Ann Allerg Asthma Im 79:113-118.
16. Migliaresi S, et al. (2000) Increased serum concentrations of soluble HLA-class I antigens in hepatitis C virus related mixed cryoglobulinaemia. Ann Rheum Dis 59:20-25.
17. Schutt P, et al. (2008) The clinical significance of soluble human leukocyte antigen class-I, ICTP, and RANKL molecules in multiple myeloma patients. Hum Immunol 69:79-87.
18. Demaria S, Bushkin Y (2000) Soluble HLA proteins with bound peptides are released from the cell surface by the membrane metalloproteinase. Hum Immunol 61:1332-1338.
19. Demaria S, Schwab R, Gottesman SR, Bushkin Y (1994) Soluble beta 2-microglobulinfree class I heavy chains are released from the surface of activated and leukemia cells by a metalloprotease. J Biol Chem 269:6689-6694.
20. Krangel MS (1986) Secretion of HLA-A and -B antigens via an alternative RNA splicing pathway. J Exp Med 163:1173-1190.
21. Tabayoyong WB, Zavazava N (2007) Soluble HLA revisited. Leuk Res 31:121-125.
22. Sidney J, et al. (2008) HLA class I supertypes: A revised and updated classification. BMC Immunol 9:1.
23. Campoli M, Ferrone S (2008) Tumor escape mechanisms: Potential role of soluble HLA antigens and NK cells activating ligands. Tissue Antigens 72:321-334.
24. Jinushi M, et al. (2005) Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class I-related chain A in advanced human hepatocellular carcinomas. J Hepatol 43:1013-1020.
25. Puppo F, et al. (2000) Soluble human MHC class I molecules induce soluble Fas ligand secretion and trigger apoptosis in activated CD8(+) Fas (CD95)(+) T lymphocytes. Int Immunol 12:195-203.
26. Spaggiari GM, et al. (2002) Soluble HLA class I molecules induce natural killer cell apoptosis through the engagement of CD8: Evidence for a negative regulation exerted by members of the inhibitory receptor superfamily. Blood 99:1706-1714.
27. Zavazava N, Kronke M (1996) Soluble HLA class I molecules induce apoptosis in alloreactive cytotoxic T lymphocytes. Nat Med 2:1005-1010.
28. Bangia N, Ferrone S (2006) Antigen presentation machinery (APM) modulation and soluble HLA molecules in the tumor microenvironment: Do they provide tumor cells with escape mechanisms from recognition by cytotoxic T lymphocytes? Immunol Invest 35:485-503.
29. Yewdell JW, Anton LC, Bennink JR (1996) Defective ribosomal products (DRiPs): A major source of antigenic peptides for MHC class I molecules? J Immunol 157:1823-1826.
30. Milner E, Barnea E, Beer I, Admon A (2006) The turnover kinetics of major histocompatibility complex peptides of human cancer cells. Mol Cell Proteomics 5:357-365.
31. Novellino L, Castelli C, Parmiani G (2005) A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother 54:187-207.
32. Parmiani G, De Filippo A, Novellino L, Castelli C (2007) Unique human tumor antigens: Immunobiology and use in clinical trials. J Immunol 178:1975-1979.
33. Baou M, et al. (2009) Involvement of Tis11b, an AU-rich binding protein, in induction of apoptosis by rituximab in B cell chronic lymphocytic leukemia cells. Leukemia 23:986-989.
34. Shimada H, et al. (2000) Analysis of genes under the downstream control of the t(8;21) fusion protein AML1-MTG8: Overexpression of the TIS11b (ERF-1, cMG1): Gene induces myeloid cell proliferation in response to G-CSF. Blood 96:655-663.
35. Meyer C, et al. (2009) New insights to the MLL recombinome of acute leukemias. Leukemia 23:1490-1499.
36. Li Y, et al. (2005) Directed evolution of human T-cell receptors with picomolar affinities by phage display. Nat Biotechnol 23:349-354.
37. Cohen CJ, et al. (2003) Direct phenotypic analysis of human MHC class I antigen presentation: Visualization, quantitation, and in situ detection of human viral epitopes using peptide-specific, MHC-restricted human recombinant antibodies. J Immunol 170:4349-4361.
38. Ishihama Y, Rappsilber J, Andersen JS, Mann M (2002) Microcolumns with selfassembled particle frits for proteomics. J Chromatogr A 979:233-239.
39. Beer I, Barnea E, Ziv T, Admon A (2004) Improving large-scale proteomics by clustering of mass spectrometry data. Proteomics 4:950-960.
40. Eng J, McCormack A, Yates J (1994) An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database. J Am Soc Mass Spectr 5:976-989.
41. Perkins DN, Pappin DJ, Creasy DM, Cottrell JS (1999) Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 20:3551-3567.
42. Parker KC, Bednarek MA, Coligan JE (1994) Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 152:163-175.
43. Andreas Schlosser RV-E (2003) Volatile polydimethylcyclosiloxanes in the ambient laboratory air identified as source of extreme background signals in nanoelectrospray mass spectrometry. J Mass Spectrom 38:523-525.
44. Rammensee H, et al. (1999) SYFPEITHI: Database for MHC ligands and peptide motifs. Immunogenetics 50:213-219.